^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

PRGN-3005

i
Associations
Company:
Precigen
Drug class:
IL-15-targeted CAR-T immunotherapy, MUC16-targeted CAR-T immunotherapy
Associations
Phase 1
Precigen, Inc
Recruiting
Last update posted :
11/13/2023
Initiation :
04/30/2019
Primary completion :
12/15/2024
Completion :
11/15/2028
BRCA
|
BRCA mutation
|
PRGN-3005